NEW YORK (GenomeWeb) – UK-based biotech company Sengenics and human genome interpretation firm Diploid of Belgium are collaborating to provide clinical exome and genome sequencing services for inherited disease diagnosis in the Middle East and in member states of the Gulf Cooperation Council, the companies said today.

"This integrated solution will be mutually advantageous in assisting both companies to work alongside doctors to enhance management of debilitating genetic disorders in the region," said Diploid CEO Peter Schols in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.